BOSTON—Columbia Laboratories, an international pharmaceutical company, has selected Manning Selvage & Lee for public relations activities to support Prochieve 8%, a natural progesterone gel which has been used for more than nine years as part of assisted reproductive technology treatment for infertile women with progesterone deficiency. MS&L’s Boston office will lead the account.
Prochieve 8% is currently being studied for use to prevent preterm birth among women who are at high risk of preterm deliveries. MS&L will initially provide support surrounding the publication of Phase III clinical trial data, as well as help the company educate professional and consumer audiences about the risks and treatments for preterm birth.
“Every day, one out of eight babies is born too soon in this country, putting the infant and mom at risk of a host of health complications,” says Robert Mills, president and chief executive officer for Columbia. “We are dedicated to helping identify ways to reduce the number of preterm births in the U.S., and we believe that MS&L’s vast expertise in this area can help us communicate with the right audiences at the right time.”